Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,734 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06209736RecruitingPhase 2
Study of OMS906 for C3G and ICGN kidney diseases
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
KaunasAges 18–99 - NCT06215846Enrolling by invitationPhase 1
Study of BioTTT001 for advanced solid tumors
This trial tests a new drug, BioTTT001, given as a shot directly into tumors. It is for people with certain advanced solid tumors that have stopped responding to standard treatments or who have no other options.
Shenyang, LiaoningAges 18–80 - NCT07503886RecruitingPhase 2
Study of an eye drop for dry eye disease
This trial tests a new eye drop called DFL24498 to see if it helps people with dry eye disease. You may qualify if your dry eye is moderate to severe and other treatments haven't worked well for you.
Chandler, ArizonaAges 18 years+ - NCT07670468RecruitingPhase 1/Phase 2
T-cell therapy for resistant viral infections after transplant or cancer treatment
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
SeoulAges 19 years+ - NCT06189495RecruitingPhase 2
Study of Genakumab for lung scarring from connective tissue disease
This study tests a new injected medication (Genakumab) for people with connective tissue disease-related lung scarring. It aims to see if it helps stabilize or improve lung function safely.
Beijing, Beijing MunicipalityAges 18–75 - NCT06186804Enrolling by invitationPhase 2
Study of ABSK021 for chronic graft-versus-host disease
This trial tests an experimental drug (ABSK021) for people with chronic graft-versus-host disease (cGvHD) after a stem cell transplant. It may help if other treatments haven't worked well enough.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06205121RecruitingPhase 2
Testing a new drug for active lung sarcoidosis
This study tests a new medication, OATD-01, for people with active sarcoidosis in their lungs. It aims to see how safe and effective the drug is and if it can improve symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06191263RecruitingPhase 2
RVU120 plus venetoclax for relapsed AML
This trial tests a new drug, RVU120, combined with venetoclax for people with AML that has come back or not responded to treatment. It may be an option if you've already tried venetoclax with another drug and it didn't work.
GrenobleAges 18 years+ - NCT06189209RecruitingPhase 2
Tenalisib for metastatic triple-negative breast cancer
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
Vijayawada, Andhra PradeshAges 18 years+ - NCT06206135Recruiting
Nephoxil capsule safety study for kidney dialysis patients
This study follows kidney dialysis patients who are starting a new medicine called Nephoxil to lower high phosphorus levels in the blood. The study will check how safe and effective the medicine is over 48 weeks.
JeonjuAges 19 years+ - NCT06191315Enrolling by invitationPhase 3
Dupilumab for asthma and wheezing in young children
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
Phoenix, ArizonaAges 2–5 - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06205342RecruitingEarly Phase 1
Stem cell treatment for chronic pancreatitis pain
This trial tests whether a new stem cell treatment can reduce the pain of chronic pancreatitis. It aims to improve your quality of life by easing long-term pain.
Charleston, South CarolinaAges 18–75 - NCT06187311RecruitingPhase 4
Rivaroxaban for atrial fibrillation patients
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
SeoulAges 19–99 - NCT06204991RecruitingPhase 1
T-cell therapy for advanced melanoma
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
HerlevAges 18–75 - NCT06205862RecruitingPhase 2
Fecal transplant for preventing colon polyp return
This study tests whether taking capsules of healthy bacteria (fecal microbiota transplant) can help prevent colon polyps from coming back after they have been removed. It might be an option for people who have had an adenoma polyp removed and want to reduce the chance of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06185751RecruitingPhase 1
Testing CS1 CAR-T for multiple myeloma
This study tests a new cell therapy called CS1 CAR-T, which helps your immune system attack myeloma cells that still grow after several other treatments. It's for people who have already tried at least three different types of therapy.
St Louis, MissouriAges 18 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT06199401Recruiting
Testing a new surgery for type A aortic tear
This trial tests a new surgical method (XJ-Procedure) for people with an acute tear in the upper part of the main artery from the heart (type A aortic dissection). It may offer a safer option for those needing 'Sun's procedure' surgery.
Xi'an, ShaanxiAges 18–70 - NCT06196255RecruitingPhase 1/Phase 2
CAR-T cell therapy for resistant or relapsed multiple myeloma
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
Xuzhou, JiangsuAges 18–70 - NCT07559370RecruitingPhase 2
Imatinib Plus Artemether-Lumefantrine for Uncomplicated Malaria
This trial tests whether adding a cancer drug called imatinib to standard malaria treatment works better and is safe. Researchers will enroll adults and children with uncomplicated malaria caused by P. falciparum parasites and monitor them in the hospital for 2–3 days.
KisumuAges 1–55 - NCT07577414Recruiting
Fetal Treatment for Congenital Diaphragmatic Hernia
This trial tests a procedure called FETO (fetoscopic endoluminal tracheal occlusion) performed during pregnancy to help babies with congenital diaphragmatic hernia—a birth defect where part of the diaphragm (breathing muscle) has a hole and organs from the belly move into the chest. The procedure temporarily blocks the baby's windpipe to help the lungs grow bigger before birth.
Ann Arbor, MichiganAges 18 years+ - NCT07650227RecruitingPhase 3
Raphamin for treating acute bronchitis in adults
This study tests whether a medicine called Raphamin can safely and effectively treat acute bronchitis (a chest infection with cough) in adults. Raphamin may help reduce cough and breathing problems in the early stages of this condition.
AramilAges 18–64 - NCT06176885RecruitingPhase 2
Immunotherapy plus chemo and targeted therapy for MSS colorectal cancer
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
Jinhua, ZhejiangAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,734 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.